In its fourth year, the mRNA Process Development & CMC Summit once again delivered three days of comprehensive insight into end-to-end process development, CMC strategies, analytical innovation, and regulatory clarity-providing attendees with the blueprint and peer connections needed to drive mRNA drug candidates toward successful approvals in 2025.
Covering programs across research, preclinical, IND-enabling, and commercial-stage pipelines, the summit addressed some of the field’s most pressing process challenges, fostering collaboration and knowledge exchange across the full spectrum of mRNA drug development.
Questions Answered Include:
How to select the best DNA starting material, from plasmid to synthetic and enzymatic, to improve IVT fidelity and reduce downstream burden?
What are the most effective in-line analytical tools for controlling dsRNA levels, capping efficiency, and impurity profiles in real time across IVT and purification?
How do we develop purification strategies that can scale and qualify novel modalities like saRNA and circRNA, without compromising product quality or stability?
What does regulatory confidence look like at global scale, and how can developers navigate platform comparability, personalized therapies, and process change approvals?
How can AI-driven predictive formulation models reduce batch failure and improve delivery in vivo, ahead of tech transfer into GMP scale-up?
Event in Numbers:
125+
Attendees from Large Pharma, Biotech, & Academia
40+
World-Class Speakers
10+
Hours of Dedicated In-Person Networking
25+
Technical Sessions & Case Studies
2
Deep Dive Tracks of Content
Organizations That Attended Include:
